1214326-89-2 Usage
Uses
Used in Chemical Research:
4-Amino-3-bromo-5-fluoropyridine is used as a research compound for the synthesis and study of various chemical reactions and processes. Its unique structure allows for the exploration of new chemical pathways and the development of novel compounds.
Used in Drug Discovery:
4-Amino-3-bromo-5-fluoropyridine is used as a lead compound in the identification and development of new pharmaceutical agents. Its presence in drug discovery pipelines can contribute to the creation of innovative treatments for various diseases and conditions.
Used in Pharmaceutical Industry:
4-Amino-3-bromo-5-fluoropyridine is used as an intermediate in the production of pharmaceuticals. Its versatile structure makes it a valuable component in the synthesis of various drugs, potentially leading to new therapeutic options for patients.
Used in Material Science:
4-Amino-3-bromo-5-fluoropyridine is used as a building block in the development of new materials with specific properties. Its incorporation into materials can lead to advancements in areas such as electronics, coatings, and specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 1214326-89-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,4,3,2 and 6 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1214326-89:
(9*1)+(8*2)+(7*1)+(6*4)+(5*3)+(4*2)+(3*6)+(2*8)+(1*9)=122
122 % 10 = 2
So 1214326-89-2 is a valid CAS Registry Number.
1214326-89-2Relevant academic research and scientific papers
TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
-
Paragraph 1307; 1308, (2021/02/12)
The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.
QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR
-
Page/Page column 32, (2021/07/24)
The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
